Uncomplicated skin abscesses are common, yet the appropriate management of the condition in the era of community-associated methicillin-resistant Staphylococcus aureus (MRSA) is unclear.
T h e ne w e ngl a nd jou r na l o f m e dicine M ore than 4 in 100 people seek treatment for skin infections annually in the United States. 1 Abscesses are the most common of these infections, and the majority of patients are treated as outpatients. 1 Serious complications, such as bacteremia, occur in rare cases. 1, 2 Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) strains, causes most skin infections, 3, 4 but the appropriate strategy for the treatment of these infections has not been defined.
Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are recommended for outpatient treatment of abscesses because of their low cost and in vitro activity against community-associated MRSA and methicillin-susceptible strains, 5 but data on their safety and efficacy are limited. One randomized trial showed that outpatients with skin abscesses treated with incision and drainage and TMP-SMX had a slightly higher cure rate than those treated with incision and drainage and placebo, which supports a role for antibiotic therapy. 6 We previously evaluated clindamycin and TMP-SMX in a randomized trial involving outpatient adults and children with large (>5 cm) or multiple skin abscesses and cellulitis (either purulent or nonpurulent). 7 Participants underwent incision and drainage, as appropriate. The cure rates associated with clindamycin were similar to those associated with TMP-SMX. However, the trial did not include the evaluation of a placebo group. Here we report the results of a double-blind, placebo-controlled trial involving children and adults with a single, small abscess. Participants were randomly assigned to receive clindamycin, TMP-SMX, or placebo after incision and drainage.
Me thods

Trial Design and Population
We conducted a multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial involving outpatients. Participants were stratified according to the presence of a surgically drainable abscess, abscess size, the number of sites of skin infection, and the presence of nonpurulent cellulitis. Participants with a single skin abscess 5 cm in diameter or smaller were randomly assigned to receive oral clindamycin, TMP-SMX, or placebo in addition to incision and drainage.
From May 2009 through January 2015, participants were recruited from urgent care clinics, emergency departments, and affiliated clinics at six sites: the University of Chicago Medical Center, Chicago; San Francisco General Hospital, San Francisco; Harbor-University of California, Los Angeles, Medical Center, Torrance; Vanderbilt University Medical Center, Nashville (added in 2011); Washington University, St. Louis (added in 2012); and Morehouse School of MedicineEmory University, Atlanta (added in 2012). All participants or their parents or guardians provided written informed consent and assent, when age-appropriate. The protocol was approved by the institutional review board at each institution. The authors vouch for the accuracy and completeness of the data and the fidelity of the trial to the protocol, available with the full text of this article at NEJM.org Participants were eligible for participation if they had a single abscess (defined as a circumscribed, drainable collection of pus) with a greatest diameter of 5.0 cm or less (≤3 cm for participants 6 to 11 months of age and ≤4 cm for participants 1 to 8 years of age), evidenced by two or more of the following signs or symptoms for at least 24 hours: erythema, swelling or induration, local warmth, purulent drainage, and tenderness to pain or palpation. Abscess size was evaluated manually by measuring the abscess cavity length in three dimensions (width, length, and depth). A standardized incision-and-drainage procedure was implemented by the treating physician, with packing of the abscess as needed. 8 Exclusion criteria included superficial skin infections (e.g., impetigo), infection at a body site requiring specialized management (e.g., perirectal, genital, or hand infection), human or animal bite, oral temperature higher than 38.5°C (or >38.0°C for children 6 to 11 months of age), presence of systemic inflammatory response syndrome criteria, immunosuppressive therapy or an immunocompromising condition (e.g., diabetes or chronic renal failure), a body-mass index (the weight in kilograms divided by the square of the height in meters) higher than 40, surgical site or prosthetic device infection, or systemic antistaphylococcal antibacterial therapy in the previous 14 days. Participants were ineligible for participation if they required hospitalization, lived in a long-term care facility, had had cancer or an inflammatory disorder treated in the previous 12 months, or had had major surgery in the previous 12 months. The full list of inclusion and exclusion criteria is provided in Table S3 in the Supplementary Appendix, available at NEJM.org.
Randomization and Study Agents
After incision and drainage of the abscess and determination of the size of the abscess, participants were randomly assigned in a 1:1:1 ratio to receive placebo, clindamycin, or TMP-SMX. Variable-block randomization was performed by an independent statistics and data-coordinating center (EMMES Corporation).
Clindamycin was given as two 150-mg tablets three times daily. TMP-SMX was given as two tablets (each containing 80 mg of trimethoprim and 400 mg of sulfamethoxazole) twice daily. Participants who were randomly assigned to receive TMP-SMX were given a placebo pill for the midday dose. Pills were over-encapsulated to prevent identification by study staff and participants. Clindamycin, TMP-SMX, and placebo capsules were identical in appearance. Pediatric doses were adjusted according to weight (Table  S4 in the Supplementary Appendix), and liquid suspensions were available for pediatric dosing. The suspensions did not differ in appearance or taste and were provided in identical medicine bottles. The study agents were administered for 10 days. Adherence was assessed by self-report and drug accountability for those participants who returned blister packs or suspension bottles.
Participants and all study staff were unaware of the study-group assignments, with the exception of the research pharmacists, who determined the correct dosing. The study medication was purchased by the study sponsor, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Microbiologic and Demographic Data
Abscess fluid was submitted for culture, species identification of isolates, and susceptibility testing in accordance with Clinical and Laboratory Standards Institute-approved methods 9 by the clinical microbiology laboratory at each participating institution. The investigators were unaware of the microbiologic results, although the results could be obtained on request by an independent data and safety monitor in the case of a treatment failure.
Participants were seen at the end of treatment (day 12), at the test-of-cure visit (7 to 10 days after the prescribed 10-day course of therapy), and at the 1-month follow-up (day 40). Information about clinical response and possible side effects of treatment or placebo were obtained with the use of standardized forms.
Statistical Analysis
The primary trial outcome was clinical cure by the time of the test-of-cure visit, stratified according to study group. Two primary efficacy analyses were performed: one in the intentionto-treat population (all participants who underwent randomization) and the other in the population that could be evaluated (participants who received treatment or placebo and completed the end-of-treatment and test-of-cure visits) (Fig. 1) . A lack of clinical cure was assessed by the research nurse at each site and was defined as lack of resolution of signs or symptoms of the infection, an inability to continue taking the study agent because of adverse effects within the first 48 hours, or any one of the following: recurrence at the original site of infection or occurrence of a skin infection at a new body site, unplanned surgical treatment of the skin infection, or hospitalization related to the infection.
The primary null hypothesis was that clindamycin, TMP-SMX, and placebo would have equivalent rates of cure at the test-of-cure visit. The trial was designed as a superiority trial with 80% power to detect a 10-percentage-point absolute difference in cure rates (e.g., 85% vs. 95%) among the three study groups in the population that could be evaluated, with an alpha of 0.05. Under the assumption of a 20% attrition rate, 786 participants were required (262 per group). The prespecified exploratory secondary outcomes were the cure rates at the end-of-treatment and 1-month follow-up visits; the cure rates in adults and children; the cure rates for patients infected with methicillin-susceptible S. aureus, MRSA, or other strains; and adverse-event rates. Comparisons among the groups were performed with the use of Pearson's chi-square test, Fisher's exact test, an analysis of variance test, or a logistic regression, as appropriate. The statistical analysis plan is available at NEJM.org. Interim analyses for safety and efficacy were performed by an independent data and safety monitoring committee with the use of an O'Brien-Fleming monitor-T h e ne w e ngl a nd jou r na l o f m e dicine Five participants underwent randomization but were not treated; 2 of these 5 underwent randomization but study agent was not dispensed, 1 recalled having taken a nonstudy drug before enrollment, and 1 received the incorrect study agent. The population that could be evaluated and was included in the secondary efficacy analysis at the 1-month follow-up included participants who missed the test-of-cure visit (TOC) but completed the 1-month follow-up visit. Patients could have been excluded from the efficacy analyses for more than one reason. TMP-SMX denotes trimethoprim-sulfamethoxazole. 
cin was assigned to 266 participants, TMP-SMX to 263 participants, and placebo to 257 participants (Fig. 1) . Five participants underwent randomization but were not treated; the studygroup assignments and reasons for withdrawal from the trial are summarized in Figure 1 . A total of 343 participants were fully adherent to the study regimen ( The difference between the cure rate in the TMP-SMX group and that in the clindamycin group was not significant (−1.3 percentage points; 95% CI, −8.4 to 5.7; P = 0.73). The results were similar for the population that could be evaluated (Table 3) , with significantly different cure rates for placebo versus either antibiotic but no significant difference between clindamycin and TMP-SMX. A new lesion at a different body site or the use of a rescue medication were more common causes of treatment failure in the placebo group than in the active-treatment groups (Table S8 in the Supplementary Appendix).
Treatment failure was rarely due to worsening of the original lesion. Logistic-regression analysis was performed to determine whether cure rates differed according to age and study group (Table 4 ). In the population that could be evaluated, children had a significantly higher cure rate with clindamycin * The actual confidence interval was 95.6% after adjustment for the interim analysis. The intention-to-treat population includes all participants who underwent randomization, and the population that could be evaluated includes participants who received treatment or placebo and completed the required study visits.
than with TMP-SMX or placebo, and this treatment advantage with clindamycin was significantly greater than that seen among adults (for the age-group differences in cure rates, P = 0.04 for clindamycin vs. TMP-SMX and P = 0.03 for clindamycin vs. placebo); there was no significant difference in cure rates between adults and children in the comparison between the TMP-SMX group and the placebo group (P = 0.87). In the intention-to-treat population, there were no significant differences between children and adults in any study-group comparisons (Table 4 ). The cure rates among participants in the intention-to-treat population who were culture-positive for S. aureus were 83.5% in the clindamycin group and 83.2% in the TMP-SMX group (P = 0.99) ( Table 3) . These rates were significantly higher than the cure rate of 63.8% in the placebo group (P<0.001 for both comparisons). The results were similar for the population that could be evaluated.
Among MRSA-infected participants in the intention-to-treat population, 81.7% of those treated with clindamycin had been cured by the time of the test-of-cure visit, as compared with 84.6% of those treated with TMP-SMX and 62.9% of those who received placebo (Table 3 ). The cure rates in the clindamycin and TMP-SMX groups did not differ significantly (P = 0.63), whereas the cure rate in the placebo group was significantly lower than that in either the TMP-SMX group (P = 0.001) or the clindamycin group (P<0.001). The results were similar for the population that could be evaluated.
Among the participants who were infected with methicillin-susceptible S. aureus in the intention-to-treat population, 89.1% of the participants in the clindamycin group were cured, as compared with 79.6% of participants in the TMP-SMX group and 65.9% of participants in the placebo group (Table 3) . The cure rate in the placebo group was significantly lower than that in the clindamycin group (P = 0.01) but not significantly lower than that in the TMP-SMX group (P = 0.16). The difference between the cure rate in the clindamycin group and that in the TMP-SMX group was not significant (P = 0.26). Similar results were observed for the population that could be evaluated. The cure rates among participants with an abscess that did not grow S. aureus in culture were similar for all treatment groups in the intention-to-treat population and the population that could be evaluated (P = 0.99 for all comparisons) ( Table 3) .
There were 13 participants with S. aureus isolates that were resistant to clindamycin -12 and age group (children vs. adults). After controlling for the effect of age, the differences between placebo and clindamycin and between placebo and TMP-SMX were significant in both the intention-to-treat population and the population that could be evaluated (P<0.001). The cure rates for clindamycin in the population that could be evaluated were significantly higher among children than among adults (among children, P = 0.04 for TMP-SMX vs. clindamycin and P = 0.03 for placebo vs. clindamycin). None of the interaction terms for the logistic-regression models were significant, indicating that the differences in cure rates between children and adults were not significant in each respective study-group comparison (P>0.05 for the intention-to-treat population and the population that could be evaluated). CI, −18.7 to −2.0; P = 0.01) were significant. The results were similar in the population that could be evaluated. At the 1-month follow-up visit among participants who had been found to be cured by the time of the test-of-cure visit, new infections at a different body site or a recurrent infection at the original body site had occurred in 6.8% (15 of 221) of clindamycin recipients, 13.5% (29 of 215) of TMP-SMX recipients, and 12.4% (22 of 177) of placebo recipients. The difference in the rates of interval or recurrent infections between the TMP-SMX and clindamycin groups was significant (6.7 percentage points; 95% CI, 0.6 to 12.8; P = 0.03), but the difference between the placebo and clindamycin groups (5.6 percentage points; 95% CI, −0.8 to 12.0; P = 0.06) and the difference between the placebo and TMP-SMX groups (−1.1 percentage points; 95% CI, −8.2 to 6.1; P = 0.88) were not significant. A new lesion at a new location or worsening of the original lesion were among the reasons for failure at the 1-month follow-up visit, although the latter reason was infrequent. There was also a nonsignificant trend toward higher rates of interval or recurrent infections among children who were treated with TMP-SMX; the rate of interval or recurrent infections in this group was 13.3% (10 of 75), as compared with 4.4% (4 of 90) in the clindamycin group, a difference of 8.9 percentage points (95% CI, 1.1 to 18.9; P = 0.05).
Adverse Events
The rate of treatment-associated adverse events was higher in the clindamycin group (21.9%) than in the TMP-SMX group (11.1%) or the placebo group (12.5%) ( Table S5 in the Supplementary Appendix). The most common adverse events were diarrhea (16.2%, 5.4%, and 6.7% respectively) and nausea (2.3%, 4.2%, and 2.4% respectively). Most adverse events were mild or moderate and resolved without sequelae (Table S6 in the Supplementary Appendix). There were no episodes of Clostridium difficile-associated diarrhea.
There were nine serious adverse events reported in 8 participants (Table S7 in the Supplementary Appendix). Eight of the events resolved without sequelae and were judged by the investigator not to be related to the study agent; these included a motor-vehicle accident, a case of status asthmaticus, a case of pneumonia, three episodes of worsening cellulitis or abscess, a new perirectal abscess, and a case of emesis. Only one episode, a hypersensitivity reaction with fever, rash, thrombocytopenia, and hepatitis, was thought by the investigator to be related to the study drug (TMP-SMX), and the reaction resolved without sequelae.
Discussion
The cure rates for simple abscesses treated with incision and drainage plus clindamycin or incision and drainage plus TMP-SMX were similar, and both cure rates were significantly higher (by 12 to 13 percentage points) than that among participants who were treated with incision and drainage plus placebo. Our findings show a clinical benefit of antibiotic therapy in addition to incision and drainage that seems limited to patients with S. aureus infection. The results complement findings from the trial conducted by Talan et al., 6 who found higher cure rates among TMP-SMX-treated participants than among placebo-treated participants in conjunction with abscess drainage (however, this trial did not include children 12 years of age or younger).
Our trial yielded other new findings. First, clindamycin was as effective as TMP-SMX, and the cure rates associated with either agent were T h e ne w e ngl a nd jou r na l o f m e dicine higher than that associated with placebo. Table  S8 in the Supplementary Appendix shows that new infections developed more frequently in participants who received placebo than among participants in either antibiotic group. Second, TMP-SMX was effective at half the dose used by Talan et al., although TMP-SMX was administered for 10 days instead of the 7 days used in that trial. 6 Third, children and adults both benefited from active therapy, although clindamycin may have performed slightly better than TMP-SMX among children. Fourth, clindamycin may be more effective than TMP-SMX in preventing recurrences or new infections after completion of therapy, particularly in children; perhaps a higher dose of TMP-SMX would have been more effective in preventing recurrent or new infections. 6 Finally, these data underscore the potential clinical relevance of in vitro resistance to clindamycin. Participants infected with a clindamycin-resistant S. aureus isolate who were treated with clindamycin had cure rates similar to those who were given placebo. The contribution of resistance to TMP-SMX to treatment failure could not be assessed because there were no resistant isolates in vitro.
The cumulative data from our investigation and that of Talan et al. 6 call into question the perception -largely based on expert opinion or smaller, underpowered, and lower-quality noninferiority trials [11] [12] [13] [14] -that cure rates do not improve with the addition of systemic antibiotic treatment after incision and drainage. 15 These two larger trials show that adjunctive antibiotic therapy improves cure rates for skin abscesses and decreases the recurrence rate.
Antibiotic-related side effects, particularly if frequent or serious, should be taken into account when deciding whether to treat a drained abscess with an antibiotic. In this trial, TMP-SMX was associated with a hypersensitivity reaction, and clindamycin was associated with more adverse events than TMP-SMX. Although no cases of C. difficile-associated diarrhea or severe allergic reactions were observed, these and other known side effects must be considered. Our findings suggest that there is a trade-off between more adverse effects and a lower likelihood of infection recurrence when one uses clindamycin rather than TMP-SMX. Such information and the local prevalence of resistance should be used by treating physicians and policy makers when choosing an antibiotic for adjunctive therapy of cutaneous abscesses.
Our trial has limitations. Two antibiotics that are commonly used and recommended for the treatment of uncomplicated skin infections were studied, but there are others that may be just as effective. For example, doxycycline (which is contraindicated for children younger than 8 years of age and was not studied in this trial) is active against MRSA strains. 16 However, given the higher cure rates that we found, the marginal benefit, if any, would probably be small at best. We followed participants for 1 month; a longer follow-up period may have captured more recurrences. 17 The potential for participants to have treatment failure but be cured of infection subsequently, such as at the 1-month follow-up visit, was not assessed (i.e., if a patient had a treatment failure at the test-of-cure visit, the patient was not evaluated at the 1-month follow-up visit). The exploratory secondary analyses we have discussed provide a potential direction for future analyses.
In conclusion, our results show that short-term outcomes among patients with uncomplicated cutaneous abscesses, particularly those caused by S. aureus, are improved by antibiotic treatment with either clindamycin or TMP-SMX in addition to abscess incision and drainage.
